Sign In
Buy PROK
$1.73
-0.170 (-8.95%)
At Close: Jun 03, 2026
ProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of “Hold” from Brokerages
01:56am, Thursday, 23'rd Oct 2025
Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have received a consensus rating of "Hold" from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Two equi
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025
07:30am, Monday, 20'th Oct 2025
WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chro
ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy
10:52am, Friday, 19'th Sep 2025
I rate ProKidney a buy due to promising Phase 2 data for rilparencel in advanced CKD, strong FDA alignment, and sufficient cash runway. PROK's Phase 3 PROACT 1 study uses eGFR slope as a surrogate end
ProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference Transcript
02:08pm, Wednesday, 03'rd Sep 2025
ProKidney Corp. (NASDAQ:PROK ) Citi's Biopharma Back to School Conference September 3, 2025 10:30 AM EDT Company Participants Bruce Culleton - CEO & Director Ethan Holdaway Conference Call Participant
WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chro
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
04:01pm, Tuesday, 12'th Aug 2025
WINSTON-SALEM, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapeutics company focused on chronic k
Meet the Biotech Stock That Rocketed 775% Higher
04:52am, Tuesday, 22'nd Jul 2025
If you're looking for stocks that can make dramatic movements in a short time frame, the biotechnology space has what you crave. At the end of June, ProKidney (PROK 2.06%) stock was languishing at les
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:01pm, Thursday, 17'th Jul 2025
PROKIDNEY CP (PROK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for July 17th
11:01am, Thursday, 17'th Jul 2025
PROK, ROKU and PHAR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 17, 2025.
New Strong Buy Stocks for July 17th
06:40am, Thursday, 17'th Jul 2025
PHAR, ROKU, PROK, MAG and KRP have been added to the Zacks Rank #1 (Strong Buy) List on July 17, 2025.
Biotech stocks can be risky but exciting investments because they can soar quickly on positive news, such as a drug approval or simply the hope that they may soon have an approved treatment. They can
ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?
01:01pm, Wednesday, 16'th Jul 2025
Does ProKidney Corp. (PROK) have what it takes to be a top stock pick for momentum investors? Let's find out.
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
07:30am, Tuesday, 15'th Jul 2025
WINSTON-SALEM, N.C., July 15, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chron
Live Nasdaq Composite: Markets Attempt Gains on Renewed Trade Deal Bets
04:02pm, Thursday, 10'th Jul 2025
Live Updates Live Coverage Has Ended X Executive Shakeup 1:06 pm by Gerelyn Terzo Uncertainty has gripped yet another one of Elon Musk’s companies after X CEO Linda Yaccarino revealed she would
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
01:31pm, Wednesday, 09'th Jul 2025
Shares of ProKidney jump 515% after its kidney cell therapy shows strong efficacy in a Phase II diabetes-related CKD study.
